Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | HCK | P08631 | 1/20 | 0.41 |
| ▸ | CIT | O14578 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.41 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227724 | 0.89 | SRC (0.46) | BRAFLCKSRCCITGAK | |
| SCHEMBL612990 | 0.82 | JAK2 (0.40) | BRAFLCKSRCCITGAK | |
| SCHEMBL226225 | 0.78 | SRC (0.55) | BRAFLCKSRCCITGAK | |
| SCHEMBL229860 | 0.76 | BRAF (0.68) | BRAFLCKSRCCITGAK | |
| SCHEMBL226245 | 0.75 | SRC (0.67) | BRAFLCKSRCCITGAK | |
| SCHEMBL41349 | 0.73 | SRC (0.62) | BRAFRAF1SRCPDGFRB | |
| SCHEMBL230056 | 0.73 | ABL1 (0.45) | BRAFLCKSRCCITGAK | |
| SCHEMBL230482 | 0.73 | SRC (0.45) | BRAFLCKSRCCITGAK | |
| SCHEMBL230483 | 0.73 | SRC (0.45) | BRAFLCKSRCCITGAK | |
| SCHEMBL230057 | 0.73 | ABL1 (0.45) | BRAFLCKSRCCITGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | claimed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | claimed |
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | MAP3K5, MAP3K1, MAP3K2 | BRAF 50/4885RAF1 35/4885LCK 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.